Company news
Spero Therapeutics, Inc. (NASDAQ:SPRO) news
Spero Therapeutics, Inc. news releases on 6ix. Latest, Mar 30, 2023: Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results…
Press releases — page 2
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
March 29, 2023
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
March 12, 2023
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
March 5, 2023
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
November 13, 2022
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
November 7, 2022
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 6, 2022
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
September 14, 2022
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
September 5, 2022
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
August 9, 2022
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 8, 2022
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
June 26, 2022
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
May 15, 2022
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
May 2, 2022
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update
March 30, 2022
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
March 16, 2022
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hosp...
February 15, 2022
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
January 18, 2022
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
January 3, 2022
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
January 2, 2022
Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update
November 9, 2021
Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
November 2, 2021
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
October 27, 2021
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
October 11, 2021
Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million
September 29, 2021
Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update
August 4, 2021
Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 28, 2021
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
June 29, 2021
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
June 14, 2021
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
May 16, 2021
Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update
May 5, 2021
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
March 10, 2021
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
March 2, 2021
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
February 4, 2021
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
January 20, 2021
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
December 16, 2020
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
December 9, 2020
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
December 1, 2020
Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update
November 4, 2020
Spero Therapeutics Announces Pricing of Securities Offering
September 10, 2020
Spero Therapeutics Announces Proposed Public Offering
September 8, 2020
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
September 7, 2020
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720
August 30, 2020
Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update
August 5, 2020
Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
July 28, 2020
Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update
May 7, 2020
Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection
May 4, 2020
Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020
May 3, 2020
Spero Announces Appointment of Scott Jackson to its Board of Directors
April 15, 2020
Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update
March 15, 2020
Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
March 10, 2020